COX-2 Retrospective Study Prompts Review By FDA, Kaiser On Merck’s Vioxx

A retrospective study conducted on COX-2s and NSAIDs has prompted reviews by FDA and Kaiser Permanente on the use of Merck's Vioxx (rofecoxib)

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet